Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833378 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
A Phase 1 study of Hepatitis C, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00833378: Completed Phase 1 study of Hepatitis C, sponsored by GlaxoSmithKline.
NCT00833378 is a Phase 1 study of Hepatitis C that has completed, run by GlaxoSmithKline. The registered enrollment target is 40 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00833378, a Phase 1 study of Hepatitis C, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I, open-label, single sequence, crossover study to be conducted in healthy adult subjects. There will be a screening visit, three treatment periods, and a follow-up visit. In Period 1, subjects will receive a single dose of eltrombopag on Day 1, and PK sampling will occur for 72 hours. In Period 2, subjects will receive LPV/RTV for 14 days with PK sampling for 12 hours. In Period 3, subjects will receive a single dose of eltrombopag with LPV/RTV on Day 1 only with PK sampling for 72 hours. Subjects will return for a follow-up visit within 10 to 14 days of the last dose of study drugs.
Conditions Studied
Interventions
- DRUG Eltrombopag
- DRUG Lopinavir/Ritonavir
- DRUG Eltrombopag and Lopinavir/Ritonavir
Study Locations (1)
New York
- GSK Investigational Site - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-01-19 |
| Est. Completion | 2009-03-11 |
| Phase | Phase 1 |
What the finished NCT00833378 record still lists
NCT00833378 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 3 interventions - of which Eltrombopag is the first listed.
NCT00833378 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00833378 about?
NCT00833378 is a clinical study titled "Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.". This is a Phase I, open-label, single sequence, crossover study to be conducted in healthy adult subjects. There will be a screening visit, three treatment periods, and a follow-up visit. In Period 1, subjects will receive a single dose of eltrombopag on Day 1, and PK sampling will occur for 72 hour...
What is the current status of trial NCT00833378?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2009-01-19. Estimated completion is 2009-03-11.
What conditions does trial NCT00833378 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT00833378?
The interventions under investigation include: Eltrombopag (DRUG), Lopinavir/Ritonavir (DRUG), Eltrombopag and Lopinavir/Ritonavir (DRUG).
Who is sponsoring clinical trial NCT00833378?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00833378 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00833378's enrollment target sits among peer trials
40 79th of 106 higher than 28 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 1
-
Open-Label Hepatic Impairment Study
COMPLETED · Phase 1
-
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805
COMPLETED · Phase 1
-
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
COMPLETED · Phase 1
-
GS-7977 With Ribavirin for Hepatitis C (SPARE)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI